napabucasin

Phase 3Small molecule

Sumitomo Pharma America, Inc.

napabucasin is one of 102 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Pancreatic AdenocarcinomaPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

napabucasin

Sumitomo Pharma America, Inc.

Phase 3

1 3

Imjudo

AstraZeneca

Preclinical

5 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Ofev

Boehringer Ingelheim

Preclinical

7 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer

Unknown status·11Globe Health Institute·Phase 3·NCT03522649·668 enrolled

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT02753127·1,253 enrolled

Adult1 trial

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT03525405·8 enrolled

Pembrolizumab1 trial

Special Combination of BBI608 and Pembrolizumab

Terminated·TTakayuki Yoshino·Phase 1/2·NCT02851004·55 enrolled

Interaction1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT03411122·30 enrolled

ESS1 trial

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT04299880·7 enrolled

2 more indications

Non-Small Cell Lung Cancer1 trial

A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

Terminated· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT02826161·4 enrolled

Pancreatic Adenocarcinoma1 trial

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT02993731·1,134 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for napabucasin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — napabucasin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for napabucasin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sumitomo Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sumitomo Pharma America, Inc.

napabucasin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

Adult1 trial

Pembrolizumab1 trial

Interaction1 trial

ESS1 trial

Non-Small Cell Lung Cancer1 trial

Pancreatic Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News